<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><label>Table 1.</label><caption><title>Application of DigiPico sequencing and MutLX analysis to a diverse set of clinical samples.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Run ID</th><th>Patient ID</th><th>Sample type</th><th>Collection site</th><th>Sequencing platform</th><th>Total UTD</th><th>Passed UTDs</th><th>Validation rate*</th><th>AUC</th></tr></thead><tbody><tr><td>D1110</td><td>#11152</td><td>Recurrence</td><td>PT2R</td><td>NextSeq</td><td>1634</td><td>4<sup>b</sup></td><td>NA</td><td>0.95</td></tr><tr><td>D1111</td><td>#11152</td><td>Recurrence</td><td>PT2R</td><td>NextSeq</td><td>1325</td><td>266</td><td>240/266<sup>c</sup></td><td>0.85</td></tr><tr><td>D1112<sup>*</sup></td><td>#11152</td><td>Recurrence</td><td>PT2R</td><td>HiSeq 4000</td><td>1219</td><td>210</td><td>189/210<sup>c</sup></td><td>0.85</td></tr><tr><td>D1511</td><td>#11152</td><td>Recurrence</td><td>PALNR</td><td>HiSeq X</td><td>1786</td><td>9</td><td>NA</td><td>0.94</td></tr><tr><td>D1210</td><td>#11152</td><td>Pre-chemo</td><td>OM</td><td>NextSeq</td><td>3139</td><td>28</td><td>16/28<sup>c</sup></td><td>0.94</td></tr><tr><td>D1211</td><td>#11152</td><td>Pre-chemo</td><td>OM</td><td>HiSeq 4000</td><td>5521</td><td>69</td><td>17/69<sup>c</sup></td><td>0.91</td></tr><tr><td>D1212</td><td>#11152</td><td>Pre-chemo</td><td>OM</td><td>HiSeq 4000</td><td>5015</td><td>24</td><td>16/24<sup>c</sup></td><td>0.94</td></tr><tr><td>D1213</td><td>#11152</td><td>Pre-chemo</td><td>OM</td><td>HiSeq 4000</td><td>5090</td><td>46</td><td>25/46<sup>c</sup></td><td>0.93</td></tr><tr><td>D1214</td><td>#11152</td><td>Pre-chemo</td><td>OM</td><td>HiSeq 4000</td><td>3415</td><td>37</td><td>27/37<sup>c</sup></td><td>0.93</td></tr><tr><td>DE011</td><td>#11513</td><td>Normal</td><td>Blood</td><td>HiSeq X</td><td>1759</td><td>7<sup>b</sup></td><td>NA</td><td>0.95</td></tr><tr><td>DE111</td><td>#11513</td><td>Pre-chemo</td><td>Ascites</td><td>HiSeq X</td><td>3685</td><td>4<sup>b</sup></td><td>NA</td><td>0.97</td></tr><tr><td>D6311</td><td>OP1036</td><td>Pre-chemo</td><td>RPCG</td><td>HiSeq X</td><td>3185</td><td>12</td><td>NA</td><td>0.96</td></tr><tr><td>DA111</td><td>#11502</td><td>Pre-chemo</td><td>LPrt</td><td>NextSeq</td><td>12511</td><td>10</td><td>NA</td><td>0.97</td></tr><tr><td>GM12885</td><td>-</td><td>Cell line</td><td>-</td><td>NextSeq</td><td>2970</td><td>3<sup>b</sup></td><td>NA</td><td>0.96</td></tr></tbody></table><table-wrap-foot><fn><p>* Run D1112 is a technical replicate of run D1111. <sup>b</sup> Runs where true UTDs are not expected to be present.<sup>c</sup> Validation through comparison with independent high-depth WGS data from the bulk of the tumor. * Validation rate is an under-estimation for the positive predictive value of clone-specific variants. PT2R: Pelvic Tumor Recurrence; PALNR: Para-Aortic Lymph Node Recurrence; OM: Omental Mass; RPCG: Right Paracolic Gutter; LPrt: Left Peritoneum; NA: Not Available; AUC: Area Under the Curve of receiver operating characteristic plot.</p><p>The study of active mutational processes using DigiPico/MutLX.</p></fn></table-wrap-foot></table-wrap>